The Janus kinase (JAK) family is one of intracellular protein tyrosine kinases (PTKs) present in hematopoietic and lymphoid cells and has been shown to play a crucial role in a variety of biological responses. It was reported that a human B-precursor leukemic cell line was potently inhibited in its proliferation by one of synthetic PTK inhibitors (tyrphostins), AG490, via anti-JAK2 activity. However, no extensive studies about it have been performed. In the present study, we tested 16 human lymphoid leukemic cell lines (B-precursor, 12; T cell, four) for their sensitivity to AG490 using 3 H-thymidine incorporation and colony formation assays, and found that B-precursor cell lines with 11q23 translocation or Philadelphia chromosome (Ph1) whose JAK2 proved to be constitutively phosphorylated were predominantly sensitive to AG490 at a concentration that has few inhibitory effect on normal hematopoiesis. We first revealed the association of JAK2 with BCR-ABL in Ph1-positive cell lines and with Bruton's tyrosine kinase (BTK) in cell lines with 11q23 translocation by coimmunoprecipitation experiments. Of interest, AG490 markedly down-regulated phosphorylation of JAK2, but rather transiently up-regulated phosphorylation of BCR-ABL and BTK, suggesting direct implication of AG490 in the process of the JAK2 dephosphorylation. These results indicate that AG490 exerts a potent inhibitory activity to B-precursor leukemia with specific chromosomal abnormalities, and a therapeutic approach using AG490 is expected. Leukemia (2001Leukemia ( ) 15, 1758Leukemia ( -1768 
Introduction
Protein tyrosine kinases (PTKs) regulate cell proliferation, cell differentiation, and signaling processes in a variety of cells. 1 The Janus kinase (JAK) family is one of the intracellular PTKs present in hematopoietic and lymphoid cells which includes JAK1, JAK2, JAK3, and Tyk2. 2, 3 The members of this family are characterized by the presence of a second kinase-like domain and the absence of SH2 and SH3 domains, and have been shown to play a crucial role in the signal transduction pathways of a variety of cytokines. 2, 3 JAKs are constitutively associated with membrane-proximal domains of cytokine receptors and become phosphorylated after ligand binding and dimerization or oligomerization of the respective receptor chains. 3 Activated JAKs consecutively phosphorylate tyrosine residues at the distal part of the receptor chains, thereby generating docking sites for signal transducers and activators of transcription (STATs) and other intracellular signaling molecules. [3] [4] [5] [6] Among JAKs, JAK2 is now known to be associated with cytokine receptors for interferon-␥ (IFN-␥), erythropoietin (EPO), thrombopoietin (TPO), granulocyte colony-stimulating factor (G-CSF), common ␤ chain-containing receptors binding granulocyte-macrophage (GM)-CSF, interleukin 3 (IL-3), and IL-5, and receptors containing gp130 in addition to hormone receptors for growth hormone and prolactin. [7] [8] [9] [10] In particular, JAK2 is essential for signaling through receptors for IFN-␥, EPO, TPO, GM-CSF, and IL-3.
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Acute lymphoblastic leukemia (ALL) is the most common cancer of childhood resulting from the clonal proliferation of lymphoid precursors with arrested maturation. 12 Chemotherapy can induce complete remission in more than 95% of cases of childhood ALL and achieve long-term disease-free survival in 70-80% of cases. However, ALL with 11q23 translocation or Philadelphia chromosome (Ph1) are still highly resistant to chemotherapy from the onset. 13 Thus, new therapeutic approaches are required to improve their prognosis. Characterization of the growth requirement of ALL cells suggested that they were dependent on various cytokines via paracrine and/or autocrine mechanism, 14, 15 in which the JAK family members are closely implicated. Accordingly, tyrosine kinase inhibitors against JAKs are expected to become a new class of anti-tumor agents.
Meydan et al 16 reported that AG490, one of the synthetic PTK inhibitors (tyrphostins), had anti-JAK2 activity and inhibited the growth of a human B-precursor leukemic cell line by induction of apoptosis with little effect on hematopoietic stem cells both in vitro and in vivo in a murine system. However, no extensive studies about a possible difference in sensitivity of human lymphoid leukemia to this JAK2 inhibitor have been performed. In the present study, we examined 16 lymphoid leukemic cell lines (B-precursor, 12; T cell, four) for their sensitivity to AG490, and showed that B-precursor cell lines with 11q23 translocation or Ph1 whose JAK2 proved to be constitutively phosphorylated were predominantly sensitive to AG490. The clinical applicability of AG490 for the treatment of these types of leukemias is also discussed.
Materials and methods

Reagents
Tyrphostins (AG490, AG126), which were synthesized from a natural tyrosine kinase inhibitor (erbstatin), were purchased from Calbiochem (La Jolla, CA, USA) and stocked in dimethyl sulfoxide. 16, 17 Their structures are shown in Figure 1 . 18, 19 Rabbit anti-mouse JAK2 20 (cross-reacting with human JAK2) and anti-human JAK3 antibodies were obtained from Upstate Biotechnology (Lake Placid, NY, USA). Anti-phosphotyrosine (PT) monoclonal antibody (mAb; 4G10) and anti-Bruton's tyrosine kinase (BTK) mAb (10D11) were also obtained from Upstate Biotechnology. Anti-JAK1 (clone 73) and anti-Tyk2 (clone 51) mAbs and anti-c-ABL mAb (8E9) were purchased from Transduction Laboratories (Lexington, KY, USA) and Pharmingen (San Diego, CA, USA), respectively. Horseradish peroxidase-conjugated goat anti-mouse IgG and anti-rabbit IgG were from MBL (Nagoya, Aichi, Japan).
Figure 1
Structures of tyrosine kinase inhibitors. (a) Natural compounds (genistein, erbstatin), which were isolated from fungal extracts and have broad-spectrum anti-tyrosine kinase activity. (b) Tyrphostins (AG490, AG126), which were synthesized from the basic structure of erbstatin.
Human leukemic cell lines and cord blood cells
Sixteen human leukemic cell lines (11q23 translocation, four; Ph1-positive, four; other B-precursor, four; T cell, four) were used in this study and their characteristics are summarized in Table 1 . Among cell lines with 11q23 translocation, KOCL-33 and KOCL-50 had t (11;19) , while KOCL-45, KOCL-69 had t(4;11). Among Ph1-positive cell lines, KOPN-30bi, KOPN57bi, and KOPN-72bi were established from patients with Ph1-ALL and had rearrangement of minor breakpoint cluster region (m-bcr), while KOPN-55bi was established from a patient with blast crisis of chronic myeloid leukemia (CML-BC) and had rearrangement of major breakpoint cluster region (M-bcr). NALM1, established from a patient with CML-BC, was also used for some experiments. All cell lines other than NALM1, NALM6, and Jurkat were established in our laboratory and have been described previously. [21] [22] [23] [24] Mononuclear cells separated from cord blood (CB-MNC) were used as a source of hematopoietic stem cells in colony-forming assays. 
Effects of tyrphostins on DNA synthesis
Cell cycle analysis
Before experiment, cells were washed, resuspended in fresh 10% FCS-RPMI medium, and incubated for 24 h for partial synchronization. The cell cycle analysis was carried out seriously (up to 96 h) after treatment with AG490 (25 m). After fixation in 70% ethanol on ice followed by washing with PBS, the cells were stained with 50 g/ml PI for 20 min on ice and used for analysis. Ten thousands events were analyzed on a FACScaliber flow cytometer (Beckton Dickinson, San Diego, CA, USA). Apoptosis was quantified by measuring signals in the hypodiploid region.
Colony-forming assays
Leukemic cell lines (1 × 10 4 cells/dish) and CB-MNC (1 × 10 5 cells/dish) were suspended in a semi-solid ␣-MEM medium containing 1% methyl cellulose, 20% FCS, 1% bovine serum albumin, and 1% 2-mercaptoethanol, and incubated in triplicate in 35-mm dishes at 37°C in 5% CO 2 for 14 days in the absence or presence of different concentrations of tyrphostins (AG490, AG126). Cytokines (2 unit/ml EPO, 10 ng/ml G-CSF, 10 ng/ml GM-CSF) were also included in colony assays for CB-MNC. In some experiments, cells were pretreated with AG490 (25 m) in 10% FCS-RPMI 1640 medium for different exposure times (3, 6, 12, 24 h), harvested, washed, and colony assays were performed in the absence of AG490. The cell aggregates of more than 50 cells were counted as colonies. In CB-MNC, the number of colonies, granulocyte colony-forming units (CFU-G), granulocyte-macrophage colony-forming units (CFU-GM), macrophage colony-forming units (CFU-M), megakaryocyte colony-forming units (CFU-Meg), erythrocyte colony-forming units (CFU-E), and mixed colony-forming units (CFU-GEMM) were separately evaluated, and the total number of colonies was calculated from a sum of numbers of these colonies.
Analysis of the JAK2 expression
Expression of JAK2 in leukemic cell lines was examined on Western blot as described previously. 21, 24 Briefly, cells were solubilized in lysis buffer (50 mm Tris-HCL, pH 7.5, 150 mm NaCl, 1% Triton X-100, 100 m sodium vanadate, 1 mm phenylmethylsulfonyl fluoride, 1 mm EDTA) for 30 min on ice. The cell lysates were separated on a 7.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel under reducing conditions and transferred to a nitrocellulose membrane. The membrane was incubated overnight at room temperature with anti-JAK2, and then incubated with peroxidase-conjugated goat anti-rabbit IgG for 1 h. The bands were developed using an enhanced chemiluminescence (ECL) kit (Amersham Pharmacia Biotech, Buckinghamshire, UK). In some experiments, expression of JAK family members other than JAK2 was also examined. 
Analysis of tyrosine phosphorylation of JAK2
Status of tyrosine phosphorylation of JAK2 in leukemic cell lines was examined using anti-PT mAb on Western blot. In brief, 1 × 10 7 cells were lysed and incubated with anti-JAK2 antibody for 3 h on ice, and the JAK2 was then immunoprecipitated using protein A-sepharose beads. The precipitates were eluted by SDS sample buffer, run on a 7.5% SDS-polyacrylamide gel, and transferred to a nitrocellulose membrane. The membrane was incubated overnight at room temperature with rabbit anti-JAK2 antibody or anti-PT mAb (1 g/ml), and then incubated with peroxidase-conjugated anti-rabbit or antimouse IgG, respectively, for 1 h. The bands were developed using an ECL kit. In some experiments, tyrosine phosphorylation of JAK family members other than JAK2 was also examined.
Analysis of molecules coimmunoprecipitated with JAK2
The JAK2 precipitates from leukemic cell lines were eluted by SDS sample buffer, run on a 10% SDS-polyacrylamide gel, and transferred to a nitrocellulose membrane. The membrane was incubated with anti-c-ABL or BTK antibody (1 g/ml) overnight at room temperature, and then incubated with peroxidase-conjugated second antibody for 1 h. The bands were developed using an ECL kit.
Changes in tyrosine phosphorylation after treatment with AG490
Using representative cell lines (KOCL-33, KOPN-55bi, KOPN-62), cells were treated with AG490 (25 m) and harvested at several time points. The changes in status of tyrosine phosphorylation of JAK2, c-ABL, and BTK were pursued on Western blot using anti-PT mAb. Changes in tyrosine phosphorylation of JAK family members other than JAK2 were also examined in some experiments.
Results
Effect of tyrphostins on DNA synthesis
To assess the inhibitory effect of AG490 on DNA synthesis, we first tested 16 leukemic cell lines for their We next compared AG490 and AG126 with regard to their ability of inhibiting DNA synthesis using four representative cell lines. As shown in Figure 2b , although the highest concentration of AG126 showed modest inhibition in the cell line with 11q23 translocation or Ph1, % inhibition by AG126 is always weaker than that by AG490 in all cell lines examined. These results suggest that a specific tyrphostin (AG490) exerts a profound inhibitory activity on lymphoid leukemic cells particularly with specific chromosomal abnormalities.
Cell cycle analysis after AG490 treatment
To examine the mechanism of growth inhibition by AG490, cell cycle analysis was performed up to 96 h after treatment with AG490 (25 m) using the representative cell line KOCL-33 with 11q23 translocation. As shown in Figure 3 , an increase in apoptotic cells which appear hypodiploid region (M1 region) was detected at 24 h and reached more than 40% of total cells at 96 h. In addition, the populations in the S and G2/M phases were gradually decreased after AG490 treatment. These results suggest that growth inhibition of leukemic cells by AG490 is mediated by a combination of induction of apoptosis and inhibition of cell cycle progression.
Leukemia
Effect of tyrphostins on colony formation
To evaluate the effect of tyrphostins on the long-term growth of leukemic cells and normal hematopoietic stem cells, we performed colony-forming assays in the absence or presence of different concentrations (5 and 25 m) of AG490 and AG126. As representatively shown in Figure 4a , the colony formation from the cell line KOCL-33 with 11q23 translocation was potently suppressed by AG490 in a dose-depen-
Figure 3
Effect of AG490 on cell cycle and induction of apoptosis. KOCL-33, the cell line with 11q23 translocation, was treated with AG490 (25 m) in 10% FCS-RPMI 1640 medium for different exposure time (12, 24, 48, 72 , and 96 h), harvested, washed, and cell cycle analysis was performed as described in Materials and methods. Horizontal and vertical axes represent DNA content and cell number, respectively. dent fashion resulting in no colony formation at 25 m, but only slightly by AG126 even at 25 m. Suppression of colony formation by AG490 was similarly observed in other cell lines examined with 11q23 or Ph1 although their % inhibition varied from 86% to 100% at 25 m of AG490 (data not shown). In contrast, the total number of colonies from CB-MNC was only slightly decreased by AG490, and not at all by AG126 even at a concentration of 25 m (Figure 4a ). The number of individual colonies (CFU-G, -GM, -M, -Meg, -E, -GEMM) also showed no significant changes by the AG490 treatment (data not shown).
To evaluate a possible clinical application of AG490 for ex vivo purging of leukemia cells, we next performed colonyforming assays in the absence of AG490 after different hours of pretreatment with AG490 (25 m). As representatively shown in Figure 4b , pretreatment of KOCL-33 with AG490 inhibited its colony formation in an exposure-time-dependent manner, and 24 h pretreatment completely abrogated the colony formation. The similar marked inhibition of colony formation by pretreatment with AG490 was also observed in the Ph1-positive cell line KOPN-55b (data not shown). In contrast, the total number of colonies from CB-MNC was not affected by pretreatment (at least up to 24 h) with AG490 ( Figure 4b) .
Analysis of the JAK2 expression
To address the possibility that different sensitivity to AG490 among leukemic cell lines depends on difference in expression of JAK2, we performed quantitative analysis of the JAK2 expression on Western blot. As shown in Figure 5 , all cell lines except for a T cell line (KOPT-11) showed almost identical quantities of JAK2 (doublets of 130/132 kDa) accompanied by similar doublets of 110/112 kDa, which might be partially degradated JAK2 proteins and have been detected in another report. 20 However, KOPT-11 showed a single band of 130 kDa accompanied by several faint bands of 80-110 kDa. These results indicated that the different sensitivity to AG490 among cell lines is not due to different quantity of the JAK2 expression.
Analysis of the JAK2 tyrosine phosphorylation
To pursue the possible association of tyrosine phosphorylation of JAK2 with inhibitory effect of AG490, we examined the status of the JAK2 tyrosine phosphorylation in leukemic cell lines ( Figure 6 ). The JAK2 phosphorylation was revealed strongly in all of the Ph1-positive cell lines (lanes 3, 5, 9 and 16) and moderately in three of four cell lines with 11q23 translocation (lanes 4, 12 and 14) and one of four other Bprecursor cell lines (lane 2). Although not clearly demonstrated in Figure 6 , the cell line with 11q23 (KOCL-45, lane 7) and other B-precursor cell line (KOPN-62, lane 11) showed modest phosphorylation of JAK2 in the longer exposed film and also in the another experiment. In contrast, no phosphorylation of JAK2 was revealed in two other B-precursor cell lines (lanes 6 and 15) and all of the T cell lines (lanes 1, 8, 10 and 13) even in the longer exposed films in repeated experiments. In comparison with the results shown in Figure 2 , these results suggest that the presence or absence of the JAK2 phosphorylation predicts the presence or absence of sensitivity to AG490 although quantities of the JAK2 phosphorylation do not always exactly correlate with those of growth inhibition by AG490. Results of maximal % inhibition by AG490 and phosphorylation status of JAK2 in leukemic cell lines are summarized in Table 1 .
Analysis of molecules coimmunoprecipitated with JAK2
Of note, several tyrosine phosphorylated molecules were coimmunoprecipitated with JAK2 as shown in Figure 6 . It has been reported that BCR-ABL chimeric protein induced JAK2 phosphorylation through the interaction of common ␤ chain of IL-3. 25, 26 Therefore, to address the possibility that the 190 or 210 kDa molecule coprecipitated with JAK2 in Ph1-positive cell lines is BCR-ABL, we stained the JAK2-immunoprecipitate blotted to the membrane with anti-c-ABL mAb. As revealed in Figure 7a , association of p190 BCR-ABL with JAK2 was demonstrated in three Ph1-positive cell lines established from ALL (lanes 1, 2 and 3), while p210 BCR-ABL in two Ph1-positive cell lines established from CML-BC (lanes 4 and 5). In NALM1 (lane 5), p145 ABL in addition to p210 BCR-ABL was also associated with JAK2.
Next, we characterized the 80 kDa molecule (p80) in Figure 6 , which was coprecipitated with JAK2 in all of the Leukemia Ph1-negative B precursor cell lines with or without 11q23 translocation (the 80 kDa band was also detectable in the lane 14 after longer exposure of the film). Of interest, in the Bprecursor cell lines NALM6 and KOPN-32 (lanes 6 and 15), the phosphorylated 80 kDa band alone was detected without visualization of the phosphorylated JAK2 band. It has been reported that Tec/BTK tyrosine kinases, a subgroup of Src tyrosine kinase family, are associated with several JAKs. 27 Therefore, to address the possibility that the 80 kDa band includes BTK, we stained the JAK2-immunoprecipitate blotted to the membrane with anti-BTK mAb. As shown in Figure 7b , association of BTK with JAK2 was demonstrated in B-precursor cell Expression of JAK2 in lymphoid leukemic cell lines. Cell lines with 11q23 translocation (lanes 1-4) , Ph1-positive cell lines (lanes 5-8), other B-precursor cell lines (lanes 9-12) , and T cell lines (lanes 13-16) were solubilized, separated on a SDS-polyacrylamide gel, and transferred to nitrocellulose membranes, which were probed with anti-JAK2 antibody and developed by ECL.
Figure 6
Status of tyrosine phosphorylation of JAK2 in leukemic cell lines. The JAK2 protein was immunoprecipitated with anti-JAK2 antibody from lysates of 16 cell lines using protein A-sepharose beads, eluted, separated on a SDS-polyacrylamide gel, and transferred to nitrocellulose membranes as described in Materials and methods. 
Inhibitory effect of AG490 on tyrosine phosphorylation of JAK2, BCR-ABL and BTK
To pursue the inhibitory effect by AG490, we examined the time course of the JAK2 tyrosine phosphorylation after AG490 treatment (25 m) using three representative cell lines. As shown in Figure 8a , tyrosine phosphorylation of JAK2 in these cell lines was down-regulated at 2 h and almost disappeared at 6 h after AG490 treatment. In contrast, tyrosine phosphorylation of p210 BCR-ABL and BTK was rather up-regulated from 3 to 6 h and returned to the previous state at 24 h after AG490 treatment (Figure 8b ). There were no changes in protein expression of JAK2, BCR-ABL, and BTK throughout the experiments (data not shown). In addition, AG126 showed no effect on tyrosine phosphorylation of JAK2, BCR-ABL, and BTK (data not shown). These results provided evidence that a molecular target of the tyrosine kinase inhibitor AG490 might be JAK2, but not tyrosine kinases associated with JAK2.
To address an inhibition mechanism of JAK2 phosphorylation by AG490, we examined whether or not the association of JAK2 with BCR-ABL or BTK is inhibited after AG490 treat- ment by coimmunoprecipitation experiments, and found that their association was not down-regulated (data not shown). In this regard, it might be conceivable that AG490 directly suppresses the phosphorylation event of JAK2, but the kinase assay using the purified JAK2 is required to conclude this and remains for future study.
Analysis of expression and tyrosine phosphorylation of JAK family members other than JAK2 and their sensitivity to AG490
To characterize specificity of AG490 to JAK2 among JAK family members, expression and status of tyrosine phosphorylation of JAK1, Tyk2, and JAK3 was first examined using representative leukemic cell lines. As shown in Figure 9a , expression of JAK1 and Tyk2 was easily and equally detected on immunoblot in all of the cell lines examined, while the JAK3 expression was very faint and almost invisible on immunoblot alone, but became visualized almost equally in all of the cell lines on immunoblot after specific immunoprecipitation of JAK3. Status of tyrosine phosphorylation of JAK1 and Leukemia Tyk2 was moderate in two (lanes 3 and 4) of two Ph1-positive and one (lane 8) of two T cell lines, modest in two (lanes 1 and 2) of two cell lines with 11q23 translocation, but not detected in two (lanes 5 and 6) of two B-precursor cell lines without Ph1 or 11q23 translocation and 1 (lane 7) of two T cell lines. However, tyrosine phosphorylation of JAK1 was not down regulated after treatment with AG490, although the 100 kDa molecule (p100) coimmunoprecipitated with JAK1 was modestly dephosphorylated (Figure 9b) . Tyrosine phosphorylation of Tyk2 was down-regulated after treatment with AG490, although its changes were slow and only partial when compared with those in JAK2 (Figure 9c ). These results suggest that an inhibitory action of AG490 is almost specifically directed to JAK2 among JAK family members. Of note, the 210 kDa molecule coimmunoprecipitated with JAK1 or Tyk2 in a Ph1-positive cell line KOPN-55bi (Figures 9b, c) proved to be p210 BCR-ABL (data not shown).
Discussion
Tyrphostins were synthesized on the basic structure of erbstain, and more than 1000 derivatives were developed.
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AG568 and AG1112 inhibit the p210 BCR-ABL tyrosine kinase activity in K562 cells and induce erythroid differentiation, 29 while AG490 and AG568 inhibit the growth of K562 cells, but not the p210 BCR-ABL tyrosine kinase activity. 30 AG82 also induces apoptosis in myeloid leukemic cell lines HL-60 and M07e. 31 Thus, it is now apparent that many tyrphostins have the inhibitory effect on cellular proliferation and differentiation.
Prompted by a new finding that AG490 specifically had anti-JAK2 activity and inhibited the growth of a human B-precursor ALL cell line, 16 we investigated the effect of AG490 on the growth of 16 lymphoid leukemic cell lines with different lineages and karyotypes. In addition, we evaluated relationship between sensitivity to AG490 and status of tyrosine phosphorylation of JAK2 and other JAK family members. We demonstrated that AG490 had a potent inhibitory effect on Bprecursor cell lines with 11q23 translocation or Ph1 without exception, and that JAK2 in these cell lines was constitutively tyrosine phosphorylated, but not or very weakly in cell lines without sensitivity to AG490, and was inhibited in its phosphorylation after AG490 treatment, whereas other JAK family members did not show correlation of their tyrosine phosphorylation with AG490 sensitivity of cell lines and was not or only modestly inhibited in their phosphorylation after AG490 treatment. These results suggest that AG490 might exert an inhibitory action via its activity capable of suppressing JAK2 phoshorylation. Considering that phosphorylated JAK2 is an active form with high tyrosine kinase activity and closely associated with induction of continuous cell cycle progression in lymphoid leukemia cells, 2 constitutive phosphorylation of JAK2 in leukemia cells with 11q23 translocation or Ph1 may be associated, at least in part, with their refractory nature to chemotherapy.
We showed that JAK2 was associated with BCR-ABL in Ph1-positive B-precursor cell lines. It is reported by Wilsor-Rawls et al 25 that BCR-ABL interacts with common ␤-chain of GM-CSF, IL-3, and IL-5 receptors and induces its tyrosine phosphorylation, and formation of this complex leads to the constitutive tyrosine phosphorylation of JAK2 in IL-3/GM-CSF-dependent MO7e cells. However, the direct association between BCR-ABL and JAK2 is not demonstrated in the paper. It is also reported by Ilaria et al 32 that introduction of bypassing the JAKs activation has been documented in myeloid leukemia cells. [33] [34] [35] In this regard, the present study might be the first demonstrating the direct association between p210 BCR-ABL /p190
BCR-ABL and JAK2 in leukemia cells. Considering that JAK2 is markedly phosphorylated in Ph1-positive B-precursor cells lines and their proliferation is profoundly inhibited by AG490 as summarized in Table 1 , it is speculated that BCR-ABL might be directly associated with and phosphorylate JAK2 in B-precursor leukemia cells. Because p210 BCR-ABL was also shown to be coimmunoprecipitated with JAK1 or Tyk2 (Figure 9b, c) , it is suggested that BCR-ABL interacts with and activates not only JAK2 but also other JAK family members.
We also showed that JAK2 was associated with BTK in Ph1-negative B-precursor cell lines. BTK tyrosine kinase was identified as the responsible gene product of human X-linked agammaglobulinemia, 36, 37 which revealed that BTK is critically involved in human B cell differentiation and activation. 38 Although the association between JAK1/JAK2 and TEC and between JAK1 and BTK has been reported in mammalian cells, 27 the present study is the first identification of the linkage between JAK2 and BTK. Of note, tyrosine phosphorylation of JAK2 was markedly down-regulated by an addition of AG490, whereas tyrosine phosphorylation of both BCR-ABL and BTK was rather transiently up-regulated, suggesting that AG490 might directly be involved in the JAK2 dephosphorylation event, but not indirectly via inhibition of tyrosine kinases associated with JAK2, and that there may exist the feedback mechanism between status of JAK2 phosphorylation and activity of its associated kinases BCR-ABL and BTK. In this regard, BTK may be contributing to constitutive phosphorylation of JAK2 in Ph1-negative B-precursor leukemia like a pivotal role of BCR-ABL in Ph1-positive B-precursor leukemia, although the molecular mechanism(s) of how BTK is constitutively tyrosine phosphorylated and active in B-precursor leukemia cells remains unknown. In addition, PTK(s) other than BTK may be implicated in the constitutive tyrosine phosphorylation of JAK2 in B-precursor leukemia particularly with 11q23 translocation, but it remains to be clarified for future study.
In addition to short-term inhibition of the growth revealed by [ 3 H]-thymidine uptake assay, AG490 inhibited the number of 14-day colonies from leukemic cell lines with 11q23 translocation or Ph1 in a dose-dependent fashion. No leukemic colony was formed at a concentration of 25 m that has little inhibitory effect on colony formation from CB-MNC. Moreover, 24-h pretreatment of these leukemic cell lines with AG490 completely abrogated colony formation, suggesting a potential role of AG490 in ex vivo purging of contaminated leukemic cells from autografts.
Recently, it was shown that AG490 suppressed cell proliferation and induced apoptosis in IL-6-dependent myeloma cells through down-regulation of mitogen-activated protein kinase and STAT3. 39 Thus, chemical blocking of the gp130 signaling pathway at the JAK level is expected to become a relevant therapeutic approach to multiple myeloma. In the mouse model of experimental autoimmune encephalomyelitis, systemic administration of AG490 effectively blocked its development in a dose-dependent manner via inhibition of adhesive activity of leukocytes without any side-effects, 40 suggesting very low toxicity of this compound even when administered in vivo.
A tyrosine kinase inhibitor CGP57148, a 2-phenylaminopyrimidine derivative, was reported to inhibit the kinase activity of p210
BCR-ABL with a high degree of selectivity 41, 42 and its therapeutic utilization has been documented. 43, 44 Systemic administration of this inhibitor was also shown to suppress the disease progression in transgenic mice with TEL/PDGFbR. 45 Thus, in Ph1-positive leukemia, a combined administration of AG490 with CGP57148 may become a useful treatment strategy as effectively shown in conjunction with STI571 (formerly CGP57148) and other anti-leukemic agents. 46 In contrast, no small molecule inhibitors for leukemia with 11q23 translocation has been known. In this regard, AG490 might represent Leukemia a novel anti-leukemic agent, alone or in combination with standardized chemotherapy, in ALL with 11q23 translocation.
